You are here: Industry Insights > NICE

News List

NHS Commercial Framework provides ‘welcome clarity’, says ABPI pharmatimes
February 26, 2021
The recently published NHS Commercial Framework provides ‘welcome clarity’ for companies seeking to partner with the NHS and the National Institute for Health and Care Excellence (NICE), according to the Association of the ...
bluebird bio’s beta-thalassaemia gene therapy rejected by NICE pharmatimes
February 20, 2021
bluebird bio’s beta-thalassaemia gene therapy betibeglogene autotemcel (beti-cel) has not been recommended by the UK’s National Institute of Health and Care Excellence (NICE) for use on the NHS.
NICE rejects Lilly’s Verzenios for advanced breast cancer pharmatimes
February 19, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of advanced breast cancer patients.
NICE recommends Beovu (brolucizumab) for treatment of wet AMD europeanpharmaceuticalreview
February 07, 2021
NICE has issued final guidance recommending Beovu (brolucizumab) to treat wet age-related macular degeneration in adults.
NICE green light for GSK's Nucala pharmatimes
February 05, 2021
GlaxoSmithKline's Nucala (mepolizumab) will be funded on the NHS in England and Wales for treating patients with severe eosinophilic asthma.
NICE launches public consultation for process review pharmatimes
February 05, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has launched a public consultation on proposals for change, made as part of its process review.
NICE recommends Revlimid for newly diagnosed multiple myeloma patients pharmatimes
January 27, 2021
Bristol Myers Squibb’s (BMS) Revlimid (lenalidomide) has received a recommendation from the UK’s National Institute of Health and Care Excellence (NICE) for newly diagnosed multiple myeloma patients.
NICE recommends new CAR T-cell therapy to treat mantle cell lymphoma europeanpharmaceuticalreview
January 26, 2021
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
NICE no for BMS’ multiple sclerosis drug Zeposia pharmatimes
January 25, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has rejected Bristol Myers Squibb’s (BMS) Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS).
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis pharmatimes
January 22, 2021
The National Institute for Health and Care Excellence (NICE) has published its final appraisal determination (FAD) recommending the use of Gilead Sciences and Galapagos’ Jyseleca (filgotinib) for the treatment of rheumatoid arthritis (RA).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page